PhD Student in Translational Research
Reference number: 2024-0301
- Heidelberg
- Full-time
- Research Group "Tumorvirus-specific Vaccination Strategies"
“Research for a life without cancer" is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.
The Research Group "Tumorvirus-specific Vaccination Strategies" at the German Cancer Research Center (DKFZ) is seeking a
The research group, led by Prof. Martin Müller, is inviting applications from highly qualified candidates for a PhD position in the project: "Antibody-Mediated Cellular Functions, Neutralization Activity, and B-Cell Responses Induced by an Anti-Human Papillomavirus Vaccine Targeting the Minor Capsid Protein L2." This project, funded by the German Cancer Aid, is part of an ongoing Phase I clinical trial investigating the prophylactic papillomavirus vaccine PANHPVAX. The aim of the PhD project is to explore the immune responses elicited in healthy volunteers following PANHPVAX vaccination.
Your Tasks
The N-terminal region of the human papillomavirus (HPV) L2 protein has been shown to contain epitopes able to induce the production of neutralizing and cross-neutralizing antibodies. Using bacterial thioredoxin as a scaffold, we managed to significantly enhance the immunogenicity of putative L2 neutralizing epitopes. In the past years, we extensively optimized the prophylactic vaccine antigen and also determined its safety in an animal model.
We now entered into a clinical development phase and are starting a phase I clinical trial (EudraCT No.: 2021-002584-22). This trial should demonstrate safety and immunogenicity. Our vaccine is based on a single molecule, is highly thermostable and more importantly, induces protective responses against all oncogenic HPV as well as a number of so called ‘low risk’ HPV. Therefore, the vaccine has the potential to provide protection against HPV also in regions where the current HPV vaccines cannot be distributed, which applies to about two thirds of all countries.
This position offers exceptional development opportunities in the rapidly evolving field of translational medicine, with a focus on the design, execution, and oversight of pre-clinical studies. The DKFZ provides an outstanding research environment, with access to state-of-the-art laboratory facilities and comprehensive material cost funding.
Your Profile
We are seeking highly motivated candidates with a master's degree in biochemistry, biology, or molecular medicine, and a strong background in immunology and/or molecular biology. The ideal candidate should be a team player with the ability to conduct independent research rigorously, while also embracing the collaborative spirit of our research group.
We Offer
Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level
Access to international research networks
Doctoral salary with the usual social benefits
30 days of vacation per year
Flexible working hours
Possibility of part-time work
Family-friendly working environment
Sustainable travel to work: subsidized Germany job ticket
Unleash your full potential: targeted training and mentoring through the DKFZ International PhD Program and DKFZ Career Service
Our Corporate Health Management Program offers a holistic approach to your well-being
Are you interested?
Then become part of the DKFZ and join us in contributing to a life without cancer!
Prof. Dr. Martin Müller
Phone: +49 (0)6221/42-4628
We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude.
